Abstract
The present study was undertaken to detect circulating IgG antibodies to peptide
antigens derived from baculoviral IAP repeat-containing protein 5 isoform 2
(BIRC5) and myc proto-oncogene protein (MYC) in cervical cancer. A total of 107
female patients with cervical cancer of stages I and II, and 130 healthy female
subjects were recruited for analysis of circulating IgG antibodies to BIRC5 and
MYC. Student's t-test showed significant differences in circulating levels of
anti-BIRC5 IgG (t = -4.27, df = 235, P < 0.0001) and anti-MYC IgG (t = 3.51,
df = 232, P = 0.0005) between the patient group and the control group. Receiver
operating characteristic (ROC) analysis showed an area under the ROC curve (AUC)
of 0.67 with sensitivity of 23.4% against specificity of 90% for the anti-BIRC5
IgG assay and an AUC of 0.66 with sensitivity of 9.4% against specificity of
90.6% for the anti-MYC IgG assay. Analysis of quality control samples gave an
inter-assay deviation of 8.9% in the anti-BIRC5 IgG assay and 9.0% in the
anti-MYC IgG assay. This work suggests that anti-BIRC5 IgG could serve as a
biomarker for early diagnosis of cervical cancer although a panel of such
tumor-associated antigens is needed to develop a highly sensitive test.
| Original language | English |
|---|---|
| Pages (from-to) | 198-201 |
| Number of pages | 4 |
| Journal | FEBS Open Bio |
| Volume | 5 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Jan 2015 |
